CStone Pharmaceuticals (HKG:2616)
Hong Kong
· Delayed Price · Currency is HKD 4.450
+0.160 (3.73%)
Jun 25, 2025, 4:08 PM HKT
CStone Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Operating Revenue | 407.21 | 463.84 | 481.36 | 243.72 | 1,039 | Upgrade
|
| Revenue | 407.21 | 463.84 | 481.36 | 243.72 | 1,039 | Upgrade
|
| Revenue Growth (YoY) | -12.21% | -3.64% | 97.51% | -76.54% | - | Upgrade
|
| Cost of Revenue | 167.05 | 159.55 | 202.99 | 106.83 | 241.42 | Upgrade
|
| Gross Profit | 240.15 | 304.3 | 278.38 | 136.89 | 797.41 | Upgrade
|
| Selling, General & Admin | 211.58 | 382.06 | 576.36 | 661.38 | 484.66 | Upgrade
|
| Research & Development | 123.93 | 501.4 | 614.16 | 1,305 | 1,405 | Upgrade
|
| Operating Expenses | 335.51 | 883.46 | 1,191 | 1,966 | 1,889 | Upgrade
|
| Operating Income | -95.36 | -579.16 | -912.15 | -1,829 | -1,092 | Upgrade
|
| Interest Expense | -15.17 | -11.82 | -8.48 | -2.24 | -1.32 | Upgrade
|
| Interest & Investment Income | 12.67 | 24.89 | 9.67 | 9.8 | 24.16 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.8 | 20.36 | 61.49 | -69.13 | -181.84 | Upgrade
|
| Other Non Operating Income (Expenses) | 13.44 | 25.71 | 8.71 | 36.02 | 27.51 | Upgrade
|
| EBT Excluding Unusual Items | -87.22 | -520.02 | -840.75 | -1,855 | -1,223 | Upgrade
|
| Gain (Loss) on Sale of Investments | 6.36 | 0.3 | -61.93 | -64.2 | 2.42 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.38 | 178.89 | - | -0.9 | - | Upgrade
|
| Asset Writedown | -10.73 | -26.4 | - | - | - | Upgrade
|
| Pretax Income | -91.21 | -367.23 | -902.68 | -1,920 | -1,221 | Upgrade
|
| Earnings From Continuing Operations | -91.21 | -367.23 | -902.68 | -1,920 | -1,221 | Upgrade
|
| Net Income | -91.21 | -367.23 | -902.68 | -1,920 | -1,221 | Upgrade
|
| Net Income to Common | -91.21 | -367.23 | -902.68 | -1,920 | -1,221 | Upgrade
|
| Shares Outstanding (Basic) | 1,276 | 1,263 | 1,173 | 1,165 | 1,046 | Upgrade
|
| Shares Outstanding (Diluted) | 1,276 | 1,263 | 1,173 | 1,165 | 1,046 | Upgrade
|
| Shares Change (YoY) | 1.04% | 7.69% | 0.66% | 11.39% | 20.69% | Upgrade
|
| EPS (Basic) | -0.07 | -0.29 | -0.77 | -1.65 | -1.17 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.29 | -0.77 | -1.65 | -1.17 | Upgrade
|
| Free Cash Flow | -343.18 | -588.86 | -610.74 | -1,575 | -575.11 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | -0.47 | -0.52 | -1.35 | -0.55 | Upgrade
|
| Gross Margin | 58.98% | 65.60% | 57.83% | 56.17% | 76.76% | Upgrade
|
| Operating Margin | -23.42% | -124.86% | -189.49% | -750.64% | -105.11% | Upgrade
|
| Profit Margin | -22.40% | -79.17% | -187.53% | -787.84% | -117.54% | Upgrade
|
| Free Cash Flow Margin | -84.28% | -126.95% | -126.88% | -646.26% | -55.36% | Upgrade
|
| EBITDA | -82.06 | -560.24 | -895.41 | -1,821 | -1,085 | Upgrade
|
| EBITDA Margin | -20.15% | -120.78% | -186.01% | - | -104.49% | Upgrade
|
| D&A For EBITDA | 13.3 | 18.93 | 16.74 | 8.76 | 6.45 | Upgrade
|
| EBIT | -95.36 | -579.16 | -912.15 | -1,829 | -1,092 | Upgrade
|
| EBIT Margin | -23.42% | -124.86% | -189.49% | - | -105.11% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.